RHO and cancer: Among them, 18 lncRNAs (SNHG11, SNHG16, ZNFX1-AS1, GAS5, RPL32P3, AC005154.5, RP5-1180C10.2, SNHG1, ZNF761, PVT1, RP11-66N24.3, RP11-1149O23.3, TMEM191A, RP11-368I7.2, AP000525.8, AL589743.2, AL589743.1, and CTD-2314B22.3) were upregulated (Figure 1(e)) and 16 lncRNAs (MAGI2-AS3, SEMA3B, RP11-65F13.2, RP11-875O11.1, PLK1S1, LINC00476, RP11-57H14.4, RP5-842K24.2, MIR22HG, RP11-500G10.1, RP11-392A22.2, MED14-AS1, WDFY3-AS2, FGD5-AS1, RP4-669P10.18, and RPL23AP79) were downregulated (Figure 1(f)) in urologic cancers compared to normal tissues.